Slide 1: Exchange filing cover letter: Investor Presentation
RPG LIFE SCIENCES LIMITED L Unit No. 208-213, B Wing, Bezzola Complex, Sion-Trombay Road, Chembur, Mumbai 400071, India Tel: +91-22-25292152-55 Fax: +91-22-25297423 RPO LIFE SCIENCES August04,2022 To The Manager BSE Limited Listing Department Corporate Relationship Department National Stock Exchange
Slide 2: Investors' Presentation Q1 FY23
RPG LIFE SCIENCES An <>>>R~G Company Investors’ Presentation Q1 FY23
Slide 3: Disclaimer
Disclaimer This presentation may include statements which may constitute forward-looking statements. All statements that address expectations or projections about the future, including, but not limited to, statements about the strategy for growth, business development, market position, expenditures,
Slide 4: RPG Life Sciences Overview
RPG Life Sciences Overview RPG Life Sciences, part of RPG Enterprises, is an integrated research based pharmaceutical Company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space. Leader in Immunosuppressants Domestic Formulations
Slide 5: RPG Life Sciences Product Portfolio
RPG Life Sciences Product Portfolio Key Therapies Key Products Immunosuppressant Portfolio Text Book Brands New Portfolio Specialty Chronic Life Cycle Management • Nephrology Azoran· '! !~!~:ti't_ 'NuGlip,! ,.!! (Existing Products) • Rheumatology Azoran· Azathioprine Trastuzumab Domestic Azathioprin
Slide 6: Key Financials, Business Highlights & Strategy
Key Financials, Business Highlights & Strategy An <l>» RPCi Company 5 L R?G LIFE SCIENCES
Slide 7: Key Highlights of Q1 FY23
Key Highlights of Q1 FY23 RPGLS continues to grow faster than the market at 20.9%* vs 6.6% (IPM)** ~ PBT continues to grow healthy double digit (30%) despite inflationary pressures and rising costs due to geo-political situations Profit margins’ upward trajectory continues – EBITDA margin reaches re
Slide 8: Company Financial Performance – Profit Margins
Company Financial Performance – Profit Margins Upward y-o-y Record setting Trajectory continues – EBITDA Margin reaches 22.5% & PBT Margin 19.5% EBITDA% 22.5% 20% PBT% 18% 19.5% 17% 16% 14% 12% 11% 10% 10% 10% 9% 8% 6% 6% 5% 4% 4% 4% 4% 1% 0% 0% All historic numbers are rounded-off to full integers
Slide 9: Key Financials: Q1 FY23
Key Financials: Q1 FY23 (All figures in Rs. Crores except EPS in Rs.) Revenue from Operations EBITDA & EBITDA Margin PBT & PBT Margin - --t - --t - -t 128.9 29.1 108.1 25.1 23.4 19.3 jJY 21.6% 22.5% 19.5% 17.8% FY22 Q1 FY23 Q1 FY22 Q1 FY23 Q1 FY22 Q1 FY23 Q1 PAT & PAT Margin EPS - -t -t 18.2 11.0 13
Slide 10: Key Financials' Trends
Key Financials’ Trends (All figures in Rs. Crores except EPS in Rs.) Revenue from Operations - --t ___t EBITDA & EBITDA Margin PBT & PBT Margin - -t 440.2 89.4 73.2 375.6 389.1 70.8 330.2 59.9 53.6 41.8 34.4 29.1 25.1 128.9 15.1 10.4% 15.9% 18.2% 20.3% 22.5% 11.1% 13.8% 16.6% 4.6% 19.5% FY19 FY20 FY
Slide 11: Key Financials' Trends
Key Financials’ Trends _f ROCE% _f ROE% Debt/Equity Ratio - -l 27.9% 0.22 23.6% 24.3% 18.5% 20.1% 16.4% 11.0% 6.7% 0.06 0.01 0.00 FY19 FY20 FY21 FY22 FY19 FY20 FY21 FY22 FY19 FY20 FY21 FY22 Company continues to remain Debt-free An <l>» RPCi Company 10 L R?G LIFE SCIENCES
Slide 12: Business Segment-wise Performance: Q1 FY23
Business Segment-wise Performance : Q1 FY23 Sales (Rs Crs) • Domestic Formulations contributed 65% to total sales of Q1 FY23 Domestic • 21% sales growth majorly driven by legacy products • Better than market growth 83.0 Formulations 68.7 • New products contribution improving consistently (currently
Slide 13: RPG Life Sciences ICRA Rating Reaffirmed in FY22
RPG Life Sciences ICRA Rating Reaffirmed in FY22 Long term rating reaffirmed at A Short term rating reaffirmed at A1 Outlook on long term rating has been retained as Stable The rating reaffirmation factors: Strong brands in the Indian Pharmaceutical Industry Considerable improvement in the opera
Slide 14: Domestic Formulations (DF)
Domestic Formulations (DF) • Operating in Mass/Mass-specialty and Specialty segments • Presence in both Acute & Chronic therapy areas • Leading Text Book Brands – Azoran, Aldactone, Lomotil, Naprosyn, Serenace, Norpace • Leading player in Immunosuppressant category • Good Customer Coverage - Cardiol
Slide 15: International Formulations (IF)
International Formulations (IF) • Strong presence in immunosuppressant segment (Azathioprine) • Footprints across Regulated and Emerging Markets - Canada, UK, Germany, France, Australia, South East Asia, Africa • Long lasting, impeccable supply track record and business relationship with some of the
Slide 16: APIs
APIs • High value, low volume, niche APIs • Mature stable molecules • Provides backward integration to International Formulations business • Footprints across geographies - LATAM, Iran, Germany, China, South Korea, Bangladesh, Egypt, India, etc. • Strong customer focus - long lasting relationship wi
Slide 17: Infrastructure & Backend Capabilities
Infrastructure & Backend Capabilities An <l>» RPCi Company 16 L R?G LIFE SCIENCES
Slide 18: Manufacturing Facilities
Manufacturing Facilities Formulations Unit 1, Ankleshwar • F1 unit caters to the domestic and emerging markets • Multipurpose plant with dedicated product lines for oral dosage forms including tablets, liquids and powder • WHO, Kenya, Nigeria approved Formulations Unit 2, Ankleshwar • F2 unit caters
Slide 19: Strong Backend Capabilities
Strong Backend Capabilities 9 - • • Quality All critical SOPs harmonized through CQA Quarterly internal audit of all plants by CQA @- • Regulatory Well established & evolved Regulatory function catering to Canada, UK, EU, Australia and emerging markets • All critical deviations, change controls and
Slide 20: Operational Highlights
Operational Highlights An <l>» RPCi Company 19 L R?G LIFE SCIENCES
Slide 21: RPG Life Sciences response to COVID-19
RPG Life Sciences response to COVID-19 A passionate call to the entire organization to go all out to ensure continuous availability of our life saving, critical medicines to our patients. Our plants did not stop even for a single day in any of the COVID waves Every patient, who asked for our critica
Slide 22: Digitalization Initiatives to Transform Business
Digitalization Initiatives to Transform Business Game Changer Customer Connect Initiative Employee Connect Initiatives Digital Platform for comprehensive ~ 2 .0 Salesforce Operations tracking: #Customer visits, customer engagement activities, sales performance analytics etc .- • Anytime, Anywhere Do
Slide 23: People Initiatives to build Performance Culture
People Initiatives to build Performance Culture with focus on Happiness I Love My Work I Feel Valued RPGLS Heroes I am Growing ~ Outperformance ~ recognition We Skill. You Grow. Competency building You Excel. We Applaud. continuum Motivation continuum •• Akanksha High 0 Career development Happiness
Slide 24: FY23 Priorities
FY23 Priorities Maintain growth momentum in top-line and bottom-line across the business segments Continue to grow our presence in chronic and specialty therapies in DF through new product launches and new customer segments Continue to build iconic/legacy brands into strategic assets Continue to enh
Slide 25: Awards & Recognitions
Awards & Recognitions An <l>» RPCi Company 24 L R?G LIFE SCIENCES
Slide 26: Jamnalal Bajaj Award for Fair Business Practices
RPG Lifesciences Awarded with ‘Jamnalal Bajaj Award for Fair Business Practices’ Jamnalal Bajaj Award for Fair Business Practices (2021-22) An <l>» RPCi Company L R?G LIFE SCIENCES
Slide 27: RPG Life Sciences Bagged Top Awards from IDMA
RPG Life Sciences Bagged Top Awards from IDMA 15th April 2022 Industry Recognition to RPG Life Sciences Best Patent Award Best Corporate Citizen Award An <l>» RPCi Company L R?G LIFE SCIENCES
Slide 28: One of India's Best Workplaces in 2020 – Top 100
RPG Life Sciences is one of India’s Best Workplace in 2020 – Amongst Top 100 • Ranked 85 amongst India's 100 Best Companies to Work For 2020 • One of India's Best Workplaces in Biotechnology & Pharmaceuticals by Great Place to Work® Institute Best Workplaces"' 0 I in Biotechnology & Pharm aceut i
Slide 29: Thank You
T H A N K Y O U An <l>» RPCi Company L R?G LIFE SCIENCES